ReviewBlood advances2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Trial
- Dynamic Frailty Assessment in Older Adults With Acute Myeloid Leukemia: From Treatment Eligibility to Treatment Adaptation.European journal of haematology · 2026Article
- Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment.European journal of haematology · 2026Review
- Shaping the future of older patients with Philadelphia-negative lymphoblastic leukemia.Haematologica · 2026Article
- Is There Still a Role for Autologous Stem Cell Transplantation in Older Adults with AML?Hematology reports · 2026Article
- A proposed refined definition of acute myeloid leukaemia patients ineligible for intensive therapy: The Integrated Comorbidity-ECOG-Age criteria.British journal of haematology · 2026Article
- Artificial Intelligence for Personalized Management of Acute Myeloid Leukemia.Journal of personalized medicine · 2026Review
- Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.Current oncology (Toronto, Ont.) · 2026Article
- Article
- Evolving Management Approaches Toward Personalized Therapy in Acute Myeloid Leukemia: A Narrative Review.Journal of personalized medicine · 2026Review
- Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.Blood neoplasia · 2026Article
- Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold?Cancers · 2026Review
- Review
- Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.European journal of haematology · 2026Article
- Fitness in CLL.Cancers · 2026Review
- Article
- Moving beyond the eyeball test for fitness assessment in AML.Blood advances · 2025Article
- Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms.Blood cancer journal · 2025Review
- Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.Cancer · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractFitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. Although several scoring systems are available to aid in determining fitness, the absence of validation studies has resulted in the lack of universally accepted assessment procedures. This limitation, combined with the increasing availability of novel agents expanding the spectrum of less-intensive options, has introduced additional complexity to the fitness assessment process. In this evolving context, fitness should reflect eligibility for a specific treatment among the several available, rather than a generic binary classification of eligibility for intensive chemotherapy. Moreover, the growing emphasis on patient-centered care, further highlights the importance of integrating quality of life, patient preferences, patient self-reported physical and social functioning status, social support, and early integration of palliative care into the assessment framework. A modern interpretation of fitness assessment should incorporate a comprehensive evaluation that extends beyond traditional clinical and biological disease characteristics. Thus, fitness assessment in patients with AML represents only 1 piece of a larger puzzle, encompassing the patient's overall capacity to sustain and benefit from a specific therapeutic program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.